{"entity":{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","aka":[],"tldr":"Defined the molecular subtypes of small-cell lung cancer and led early trials of DLL3-targeted therapy.","summary":"Charles Rudin led the consensus that split small-cell lung cancer into ASCL1, NEUROD1, POU2F3 and inflamed subtypes, giving the disease its first biology-based classification. He was a lead investigator of the rovalpituzumab tesirine and tarlatamab DLL3 programmes and of KEYNOTE-604. His laboratory studies SCLC plasticity and lineage transformation of EGFR-mutant lung cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rudin%20CM%5BAuthor%5D%20small%20cell%20lung"}],"tags":["sclc","biology","dll3"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":["dll3"],"drugs":["tarlatamab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["dellphi-304"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Small-cell lung cancer","SCLC molecular subtypes","DLL3","Neuroendocrine carcinoma biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rudin%20CM%5BAuthor%5D%20small%20cell%20lung"}],"papers":[{"title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","journal":"Nature Reviews Cancer","year":2019,"doi":"10.1038/s41568-019-0133-9"},{"title":"Small-cell lung cancer","journal":"Nature Reviews Disease Primers","year":2021,"doi":"10.1038/s41572-020-00235-0"}],"orcid":"0000-0001-5204-3465"},"route":"/people/charles-rudin/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/"}],"journal":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/"}],"paper":[{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/"},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/"},{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/"}]}}